Syntis Bio Inc.
Boston, MA R&D
- UEI
- NG1VDVGBHC87
- CAGE
- 9LAX3
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 135 Morrissey Blvd o 101, Dorchester, MA 02125, USA
- Website
- syntis.bio
- Employees
- 1-10
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Syntis Bio Inc.
Syntis Bio Inc. is a for-profit corporate entity registered in SAM.gov, located in Boston, Massachusetts, with a focus on developing innovative therapeutic technologies for complex metabolic disorders. The company's R&D Division specializes in creating novel oral enzyme therapies and gastrointestinal delivery platforms, with a particular emphasis on rare genetic and metabolic conditions. Through its research, Syntis Bio has developed a proprietary Gastrointestinal Synthetic Epithelial Lining (GSEL) technology, which appears to be a key innovative approach for improving the oral delivery of therapeutic compounds.
The company has been awarded multiple federal grants from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Institute of Child Health and Human Development (NICHD), focusing on developing advanced treatments for specific metabolic disorders. Their grant-funded projects include developing oral therapies for homocystinuria, Maple Syrup Urine Disease (MSUD), and obesity intervention. Specifically, Syntis Bio is creating enzyme-based therapies such as SYN-202 for homocystinuria, SYNT-213 for MSUD, and an oral pill designed to mimic gastric bypass surgery effects. These projects involve sophisticated approaches like protease-stable enzymes, gastrointestinal synthetic epithelial linings, and innovative oral formulations aimed at addressing metabolic dysregulation and improving patient treatment options for rare and challenging medical conditions.
Quick answers
What is Syntis Bio Inc.'s UEI?
Syntis Bio Inc.'s Unique Entity ID (UEI) in SAM.gov is NG1VDVGBHC87.
What is Syntis Bio Inc.'s CAGE code?
Syntis Bio Inc.'s CAGE code is 9LAX3.
What is Syntis Bio Inc.'s primary NAICS code?
Syntis Bio Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Syntis Bio Inc. located?
Syntis Bio Inc.'s physical address in SAM.gov is 135 Morrissey Blvd o 101, Dorchester, MA 02125, USA.
Is Syntis Bio Inc. registered in SAM.gov?
Yes. Syntis Bio Inc.'s SAM.gov registration is active through September 16, 2027.
What is Syntis Bio Inc.'s most recent federal award?
Syntis Bio Inc.'s most recent federal contract award is Optimal: oral platform for therapeutic intestinal metabolic and local-delivery (140D042690022), from Interior Business Center, on September 2, 2026.
On GovTribe
See Syntis Bio Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors